Back to top Open menu arrow
Purchase PDF

Save Save

Cite Cite

Reprints
Sections
METHODS RESULTS DISCUSSION Clinical Points
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

Meta-Analysis Early Career Psychiatrists February 23, 2021

Single Versus Multiple Daily Dosing Regimens of Psychotropic Drugs for Psychiatric Disorders: A Systematic Review and Meta-Analysis

; ; ; ; ;

J Clin Psychiatry 2021;82(2):20r13503

Abstract

Objective: To compare efficacy and safety of single daily dosing (Single-DD) vs multiple daily dosing (Multiple-DD) regimens of psychotropic drugs, the authors conducted a systematic review and meta-analysis.

Data Sources: A systematic literature search of MEDLINE and Embase was conducted with keywords related to dosing regimens and psychotropic drugs (last search: December 30, 2019)

Study Selection: Randomized controlled trials comparing clinical outcomes between Single-DD and Multiple-DD of the same formulation of the same psychotropic drugs in patients with psychiatric disorders were included.

Data Extraction: Data on study discontinuation, psychopathology, and treatment-emergent adverse events (TEAEs) were extracted.

Results: A total of 32 studies with 34 paired comparisons involving 3,142 patients met the eligibility criteria and were included in the meta-analysis. Various types of psychotropic drugs were examined: antidepressants (22 comparisons), antipsychotics (7 comparisons), benzodiazepines (2 comparisons), mood stabilizers (2 comparisons), and antidepressant-benzodiazepine combination (1 comparison). There was no significant difference in study discontinuation due to all causes (30 comparisons, N = 2,883, risk ratio [RR] = 1.01, 95% CI = 0.94 to 1.09, P = .77), lack of efficacy (22 comparisons, N = 2,307, RR = 1.06, 95% CI = 0.84 to 1.33, P = .62), or adverse events (25 comparisons, N = 2,571, RR = 0.93, 95% CI = 0.75 to 1.14, P = .47) between the Single-DD and Multiple-DD groups. No significant difference was found in changes in psychopathology (8 comparisons, N = 1,337, standardized mean difference = 0.00, 95% CI = −0.11 to 0.11, P = .99) between the 2 groups. These results were also true for any type of psychotropic drugs. In terms of TEAEs, however, there were significant differences in anxiety (4 comparisons, N = 347, RR = 0.53, 95% CI = 0.33 to 0.84, P = .007) and sleepiness (3 comparisons, N = 934, RR = 0.82, 95% CI = 0.68 to 0.99, P = .04) in favor of the Single-DD group.

Conclusions: The findings suggest Single-DD can be clinically adopted regardless of type of psychotropic drugs in patients with psychiatric disorders in general.

  1. Takeuchi H, Powell V, Geisler S, et al. Clozapine administration in clinical practice: once-daily versus divided dosing. Acta Psychiatr Scand. 2016;134(3):234–240. PubMed CrossRef NLM
  2. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226. PubMed CrossRef NLM
  3. Ryan R, Santesso N, Lowe D, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. Cochrane Database Syst Rev. 2014;(4):CD007768. PubMed NLM
  4. Takeuchi H, Fervaha G, Lee J, et al. Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia. Eur Neuropsychopharmacol. 2015;25(3):295–302. PubMed CrossRef NLM
  5. Sun X, Hamer R, McEvoy J. Asenapine once daily versus twice daily: impact on patient acceptance in a randomized, open-label, 14-day clinical trial. J Clin Psychiatry. 2015;76(7):992–993. PubMed CrossRef NLM
  6. Chengappa KN, Parepally H, Brar JS, et al. A random-assignment, double-blind, clinical trial of once- vs twice-daily administration of quetiapine fumarate in patients with schizophrenia or schizoaffective disorder: a pilot study. Can J Psychiatry. 2003;48(3):187–194. PubMed CrossRef NLM
  7. Voris JC, Shaurette GN, Sebastian PS, et al. Nefazodone: single versus twice daily dose. Pharmacotherapy. 1998;18(2):379–380. PubMed PubMed NLM
  8. Amsterdam JD, Hooper MB, Amchin J. Once- versus twice-daily venlafaxine therapy in major depression: a randomized, double-blind study. J Clin Psychiatry. 1998;59(5):236–240. PubMed CrossRef NLM
  9. Newburn G, Edwards R, Thomas H, et al. A comparison of the efficacy and tolerability of moclobemide given as a single daily dose or in three divided doses per day for the treatment of patients with a major depressive episode (DSM-III-R). J Clin Psychopharmacol. 1995;15(suppl 2):10S–15S. PubMed CrossRef NLM
  10. Doongaji DR, Sheth AS, Apte JS, et al. A comparative study of single and multiple doses of clobazam vs diazepam in anxiety neurosis. Current Therapeutic Research. 1985;37(3):398–405.
  11. Ansseau M, Doumont A, von Frenckell R, et al. Duration of benzodiazepine clinical activity: lack of direct relationship with plasma half-life: a comparison of single vs divided dosage schedules of prazepam. Psychopharmacology (Berl). 1984;84(3):293–298. PubMed CrossRef NLM
  12. James RT, Dean BC. A comparison of a single night-time and a divided daily dosage regimen of a chlordiazepoxide/amitriptyline combination. Curr Med Res Opin. 1980;6(8):573–575. PubMed CrossRef NLM
  13. Weisler RH, Kalali AH, Cutler AJ, et al. Efficacy and safety of once- versus twice-daily carbamazepine extended-release capsules for the treatment of manic symptoms in patients with bipolar I disorder. Psychiatry (Edgmont). 2008;5(3):35–48. PubMed NLM
  14. Singh LK, Nizamie SH, Akhtar S, et al. Improving tolerability of lithium with a once-daily dosing schedule. Am J Ther. 2011;18(4):288–291. PubMed CrossRef NLM
  15. Yildiz A, Pauler DK, Sachs GS. Rates of study completion with single versus split daily dosing of antidepressants: a meta-analysis. J Affect Disord. 2004;78(2):157–162. PubMed CrossRef NLM
  16. Yýldýz A, Sachs GS. Administration of antidepressants: single versus split dosing: a meta-analysis. J Affect Disord. 2001;66(2–3):199–206. PubMed NLM
  17. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(7716):b2535. PubMed NLM
  18. Watson JM, Tiplady B. Zimelidine: comparison of different dosage regimes in general practice. Acta Psychiatr Scand suppl. 1981;290:464–470. PubMed CrossRef NLM
  19. Siddiqui UA, Chakravarti SK, Jesinger DK. The tolerance and antidepressive activity of fluvoxamine as a single dose compared to a twice daily dose. Curr Med Res Opin. 1985;9(10):681–690. PubMed CrossRef NLM
  20. Wheatley D. Trazodone in depression. Int Pharmacopsychiatry. 1980;15(4):240–246. PubMed CrossRef NLM
  21. Pearce JB, Rees WL. A double-blind comparison of three times daily and single night dosage of the tricyclic anti-depressant dothiepin. J Int Med Res. 1974;2(1):12–19. CrossRef
  22. Mendels J, Schless A. A controlled comparison of doxepin h.s. and doxepin q.i.d. J Clin Pharmacol. 1975;15(7):534–539. PubMed CrossRef NLM
  23. Snowdon JA. Double-blind comparison of 3-times daily and single night dosage of amitriptyline, with special reference to side-effects. Curr Med Res Opin. 1976;4(6):381–387. PubMed CrossRef NLM
  24. Frank P. Comparisons of various clomipramine (Anafranil) dosage regimes. J Int Med Res. 1977;5(1 suppl):11–15. PubMed NLM
  25. Mendels J, Schless AP. Antidepressant effects of desipramine adminstered in two dosage schedules. Dis Nerv Syst. 1977;38(4):249–251. PubMed NLM
  26. Montgomery S, McAuley R, Montgomery DB. Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens. Br J Clin Pharmacol. 1978;5(suppl 1):71S–76S. PubMed NLM
  27. Schubert DS, Miller SI. Are divided doses of tricyclic antidepressants necessary? J Nerv Ment Dis. 1978;166(12):875–877. PubMed CrossRef NLM
  28. De Maio D, Sesso M, Levi Minzi A, et al. Evaluation of the clinical efficacy of single daily doses of antidepressants. Prog Neuropsychopharmacol. 1980;4(6):607–612. PubMed CrossRef NLM
  29. Weise CC, Stein MK, Pereira-Ogan J, et al. Amitriptyline once daily vs three times daily in depressed outpatients. Arch Gen Psychiatry. 1980;37(5):555–560. PubMed CrossRef NLM
  30. Sharma SD. A comparison of a divided and a single dose regime of dothiepin and its therapeutic efficacy. Indian J Psychiatry. 1981;23(4):355–359. PubMed NLM
  31. Ban TA, Fujimori M, Petrie WM, et al. Systematic studies with amoxapine, a new antidepressant. Int Pharmacopsychiatry. 1982;17(1):18–27. PubMed CrossRef NLM
  32. Mungavin JM, Ankier SI. Comparison of two dosage regimens of trazodone in the treatment of depression. Clin Trials J. 1983;20(4):181–188.
  33. Brooks D, Prothero W, Bouras N, et al. Trazodone: a comparison of single night-time and divided daily dosage regimens. Psychopharmacology (Berl). 1984;84(1):1–4. PubMed CrossRef NLM
  34. Wheatley D. Trazodone: alternative dose regimens and sleep. Pharmatherapeutica. 1984;3(9):607–612 PubMed NLM
  35. Davey A. A comparison of two oral dosage regimens of 150 mg trazodone in the treatment of depression in general practice. Psychopharmacology (Berl). 1988;95(suppl):S25–S30. PubMed CrossRef NLM
  36. Nair NP; The Risperidone Study Group. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. J Clin Psychopharmacol. 1998;18(2):103–110. PubMed CrossRef NLM
  37. Agarwal V, Chadda RK. Once daily risperidone in treatment of schizophrenia. Indian J Psychiatry. 2001;43(1):32–35. PubMed NLM
  38. Takeuchi H, Fervaha G, Uchida H, et al. Impact of once- versus twice-daily perphenazine dosing on clinical outcomes: an analysis of the CATIE data. J Clin Psychiatry. 2014;75(5):506–511. PubMed CrossRef NLM
  39. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62. PubMed NLM
  40. Heel RC, Morley PA, Brogden RN, et al. Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1982;24(3):169–206. PubMed NLM
  41. Medic G, Higashi K, Littlewood KJ, et al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2013;9:119–131. PubMed CrossRef NLM
  42. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527–539. PubMed NLM
  43. Caldeira D, Vaz-Carneiro A, Costa J. The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis. Rev Port Cardiol. 2014;33(7–8):431–437. PubMed CrossRef NLM
  44. Kurose S, Mimura Y, Uchida H, et al. Dissociation in pharmacokinetic attenuation between central dopamine D2 receptor occupancy and peripheral blood concentration of antipsychotics: a systematic review. J Clin Psychiatry. 2020;81(5):19r13113. PubMed CrossRef NLM
  45. Arakawa R, Tateno A, Kim W, et al. Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: a positron emission tomography study with [(11)C]DASB. Psychiatry Res Neuroimaging. 2016;251:1–6. PubMed CrossRef NLM
  46. Takano A, Suzuki K, Kosaka J, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl). 2006;185(3):395–399. PubMed CrossRef NLM
  47. Chung YC, Park TW, Yang JC, et al. Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol. J Clin Psychopharmacol. 2012;32(6):778–786. PubMed CrossRef NLM
  48. Kittipeerachon M, Chaichan W. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: a pragmatic double-blind randomized trial. Schizophr Res. 2016;176(2–3):231–238. PubMed CrossRef NLM

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

Save Save

Cite Cite

Vol 86 • 2025 • Number 2

Read the Current Issue

Original Research

Incidence and Risk Factors for Suicide Attempt During Pregnancy and Postpartum

Original Research

Valbenazine in Elderly Adults With Tardive Dyskinesia

Academic Highlights

Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report

Original Research

Older Adults Visiting Emergency Departments for Mental Health Issues:A CHIRPP Database Study

Consensus Statement

Developing a Treatment-Resistant Depression Consultation Program, Part I: Practical and Logistical Considerations

Brief Report

Psychosocial Correlates of Optimism among US Military Veterans
View current Issue

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe